Bluejay Diagnostics “announced that it has entered into a definitive agreement for the purchase and sale of 216,000 shares of the Company’s common stock at a purchase price of $7.365 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 216,000 shares of its common stock. The warrants will have an exercise price of $7.24 per share and will be immediately exercisable upon issuance for a period of five years. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 28, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BJDX:
- Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Bluejay Diagnostics maintains Symphony Il-6 regulatory submission timeline
- Bluejay Diagnostics reports Q2 EPS ($2.75) vs ($2.00) last year
- Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
- Bluejay Diagnostics Inc trading resumes